Work

Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL

Year: 2016

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2016-858

Authors: Denise M. Wolf, Christina Yau, Ashish Sanil, Lamorna Brown-Swigart, Gillian Hirst, Meredith Buxton, Melissa Paoloni, I-SPY 2 TRIAL Investigators, Olufunmilayo Olopade, Hope Rugo, Angela De Michele, Fraser Symmans, Don Berry, Laura Esserman, Laura van ‘t Veer

Institutions: University of California, San Francisco, Berry Consultants, LLC (United States), Quantum Leap Healthcare Collaborative, University of Chicago, University of Pennsylvania

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2483524364

Cites:

Cited by: 2

Related to: 10